Leiomyosarcoma is not typically inherited. The vast majority of cases arise from random genetic changes that accumulate over a person’s lifetime, not from mutations passed down through families. That said, a small but meaningful fraction of cases do occur in people who carry inherited gene mutations that raise their cancer risk. Leiomyosarcoma affects roughly 6 out of every million people in the United States, and recent estimates suggest up to 20% of all sarcomas may have some link to cancer predisposition genes.
Why Most Cases Are Sporadic
Leiomyosarcoma develops in smooth muscle tissue, which lines organs like the uterus, stomach, blood vessels, and intestines. In most patients, the cancer results from somatic mutations, meaning genetic errors that happen in individual cells during a person’s life rather than being present at birth. These errors can’t be passed to children. No single environmental cause has been pinpointed for most cases, which is why leiomyosarcoma is generally considered sporadic.
When researchers use rigorous statistical methods to identify how many sarcoma patients carry an inherited genetic explanation, the confirmed yield is closer to 9%. The gap between that number and the broader 20% estimate reflects how many families show suspicious cancer patterns that haven’t yet been traced to a specific gene. In practical terms, this means roughly 1 in 10 leiomyosarcoma patients may carry a hereditary component, while the rest developed the disease without a clear inherited cause.
Li-Fraumeni Syndrome and TP53 Mutations
The strongest known hereditary link to leiomyosarcoma is Li-Fraumeni syndrome (LFS), a rare condition caused by inherited mutations in the TP53 gene. TP53 normally acts as one of the body’s most important tumor suppressors, essentially a brake on uncontrolled cell growth. When someone inherits a faulty copy, their lifetime cancer risk is dramatically elevated across multiple cancer types.
Soft tissue sarcomas, including leiomyosarcoma, are one of the five core cancers associated with LFS. They account for 17% to 27% of all cancers that develop in people with the syndrome. The cumulative lifetime incidence of soft tissue sarcoma in LFS is about 15% for women and 22% for men. In children with LFS, soft tissue sarcomas are the single most common cancer type. If you or a close relative has been diagnosed with leiomyosarcoma alongside other LFS-associated cancers (breast cancer, brain tumors, bone cancer, or adrenal gland tumors), that pattern is a strong signal for genetic evaluation.
A population-based study using Utah’s genealogical database found that patients with non-uterine leiomyosarcoma were more likely than the general population to meet clinical criteria for LFS genetic testing. The researchers also noted that colorectal cancer, while not officially part of the LFS spectrum, shows up more often in LFS families. Their conclusion: family history should be evaluated broadly, not limited to a narrow checklist of LFS cancers.
Hereditary Retinoblastoma and RB1 Mutations
People who survived hereditary retinoblastoma, a childhood eye cancer caused by inherited mutations in the RB1 gene, face an increased risk of developing leiomyosarcoma later in life. The RB1 gene, like TP53, is a tumor suppressor, and losing its function leaves cells vulnerable to becoming cancerous decades after the original retinoblastoma is treated.
In a study of 525 women with hereditary retinoblastoma, seven developed uterine leiomyosarcoma. The cumulative risk by age 50 was 3.2%, which may sound small but is dramatically higher than the general population’s risk. The excess risk also climbs sharply with age: it roughly quintuples between a woman’s 30s and her 40s. The average age of leiomyosarcoma diagnosis in these patients was 41, with a range of 32 to 52. Leiomyosarcoma is the most common soft tissue sarcoma subtype to develop as a secondary cancer in hereditary retinoblastoma survivors.
HLRCC and the FH Gene
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a syndrome caused by inherited mutations in the FH gene, which provides instructions for an enzyme involved in energy production inside cells. People with HLRCC develop benign smooth muscle tumors (leiomyomas) in the skin and, in women, the uterus. They also face an elevated risk of an aggressive form of kidney cancer.
Whether HLRCC meaningfully increases the risk of leiomyosarcoma, specifically the malignant version of smooth muscle tumors, remains genuinely uncertain. In the original description of the syndrome, 2 of 11 women with uterine fibroids also had uterine leiomyosarcoma. To date, only six women with confirmed FH mutations have been reported with uterine leiomyosarcoma worldwide, and none of those cases came from North American studies. The current understanding is that most families with FH mutations do not appear highly predisposed to leiomyosarcoma, though a few individual families may be. Researchers have flagged this as a question that urgently needs a definitive answer.
If you have HLRCC, pathologists can test tissue from skin leiomyomas for loss of the FH protein using a staining technique. This test has about 70% to 75% sensitivity and nearly 98% specificity for detecting the syndrome, making it a useful screening tool.
BRCA2 and DNA Repair Gene Changes
BRCA2 is best known for its role in breast and ovarian cancer, but it also appears to play a role in uterine leiomyosarcoma specifically. A comprehensive genomic analysis found that uterine leiomyosarcoma was the only sarcoma subtype significantly enriched for BRCA2 alterations, with about 4.7% of uterine leiomyosarcomas carrying these changes. Across all sarcoma types studied, leiomyosarcoma accounted for nearly half of all BRCA1 and BRCA2 alterations, and BRCA2 was the most commonly altered DNA repair gene overall.
An important distinction here: the BRCA2 changes found in uterine leiomyosarcoma were overwhelmingly somatic deletions (acquired by the tumor, not inherited). This means they developed within the tumor itself rather than being present in every cell of the patient’s body. The clinical relevance is that these tumors may respond to a class of targeted drugs called PARP inhibitors, which exploit weaknesses in DNA repair. But for the question of heredity, these BRCA2 changes do not, in most cases, indicate a family risk.
When Genetic Testing Makes Sense
Genetic testing is not routinely recommended for every leiomyosarcoma patient, but certain patterns in your personal or family medical history raise the likelihood of an underlying hereditary syndrome. Red flags include being diagnosed with leiomyosarcoma at an unusually young age, having multiple primary cancers, or having close relatives with cancers in the LFS spectrum (breast cancer, brain tumors, bone sarcomas, adrenal tumors, or other soft tissue sarcomas).
If you survived hereditary retinoblastoma as a child, your medical team should be aware of the elevated leiomyosarcoma risk, particularly for uterine leiomyosarcoma in women over 30. For women with confirmed HLRCC, the question of leiomyosarcoma risk is still being studied, but awareness and gynecologic monitoring are reasonable.
Population-level data suggests that family history should be assessed broadly. A family with multiple cancer types, even if they don’t fit neatly into one recognized syndrome, may still warrant genetic counseling. Testing can identify inherited mutations that change screening recommendations not just for the patient, but for their relatives as well.